Prosidion is a biopharmaceutical company focused on discovering, developing and commercializing innovative molecular targeted therapies addressing major unmet medical needs in type 2 diabetes and obesity. Prosidion is located in Oxford, in the UK close to a seat of international academic excellence. The company has state of the art facilities and fully integrated capabilities in research and development.
Prosidion is the owner/licensor of a highly profitable DPP-IV inhibitor patent estate and has licensing rights to a portfolio of DPP-IV inhibitor medical use patents with claims covering DPP-IV inhibitors as a target for lowering glucose in type 2 diabetes and related claims. A number of non-exclusive licenses to the patent estate have been granted to major pharmaceutical companies. As a consequence Prosidion is not only scientifically strong, but also financially successful.